‘s once-daily arthritis and pain medication, the approval of the U.S. Food and Drug Administration for reducing the signs and symptoms of the most prevalent forms of JRA in children two years and older and with a minimum weight of 22 pounds. VIOXX is now the first and only COX-2-specific inhibitor for the treatment of JRA approved based on clinical trials that established safety and efficacy in children aged 2 years and weighing at least 22 kg. – ‘Reduce as pediatric rheumatologist, my immediate goal when treating a child or adolescent with JRA to inflammation or swelling of the joints pain associated with pain associated with,’said study investigator Elizabeth Candell Chalom, Director of Pediatric Rheumatology, Saint Barnabas Pediatric Subspecialty Center in Livingston, NJ ‘With the approval of VIOXX for JRA, we now have a new treatment option that has been shown to be effective in relieving joint pain.
A one-year open – label extension of the pivotal study was also conducted to assess the long-term safety of VIOXX.. Approval was based on the largest JRA study ever conducted – The FDA approval of VIOXX for JRA JRA on the largest study ever conducted, which was based included 310 children and adolescent patients aged 2 to 17 with active polyarticular JRA or Pauciarticular. Results from the pivotal 12-week, multinational, double-blind study showed once daily VIOXX provided measurable improvements in reducing joint pain.Scientist Dr gender difference in the anti-TNF treating rheumatoid arthritis.
Findings announced today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain disclose the treatment mismatch between female and male patients with rheumatoid arthritis . Data from a study at Karolinska Institutet, Swedish, that women obtained anti-TNF during a higher perceived activity of the disease, and reporting reporting severe pain than her male colleagues.
DAS28 Partituren in the early anti-TNF treatment proved to be significantly higher for women than for men and wives had high on invitation joint counts . However, the doctor terminating were equivalents global healthcare reviews for males and females. Ronald van Vollenhoven commented: This study shows the meaning of taking account both of objective and the subjective measurement of scores in treating decisions The time Our hope is that this data will help reparations this imbalance and equal treatment of the prescribe and disease management for all.